Combination therapies for the optimisation of Bispecific T-cell Engagers in cancer treatment
Open accessThe DOI matches its Crossref record; 84 of the 115 references it cites were found in a registry or an index.
Abstract
Summary: Bispecific T-cell engagers (BiTEs) redirect endogenous T-cell populations to cells expressing tumour-associated antigens to induce tumour cell killing. This inherently relies upon a cytotoxic T-cell population that is able to be recruited. In many cancers, immune checkpoints and other immunosuppressive factors in the tumour microenvironment lead to a population of anergic T-cells which cannot be redirected to tumour killing and thus impede the efficacy of BiTE therapy. Furthermore, there is evidence that BiTE therapy itself can increase immune checkpoint expression, and this is thought to be a major escape mechanism for the BiTE therapy blinatumomab. To overcome these inadequate T-cell responses, BiTEs may be combined with checkpoint inhibitors, chemotherapy, costimulatory molecules or oncolytic viruses. Study of these combinations is needed to expand the use of BiTEs in solid malignancies. This review covers the rationale, preclinical evidence and any clinical trials for these combination therapies and a few other less-studied combinations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1. The cancer-immunity cycle (adapted from [1]). Tumour cell death leads to release of antigens which are taken up by antigen presenting cells (APCs). These travel to lymph nodes and activate lymphocytes, including cytotoxic T-lymphocytes (CTLs) which travel to the tumour site in the circulation and to the infiltrate by extravasation. These infiltrating CTLs cause tumour cell lysis which releases further tumour antigens that perpetuate the cycle. Produced using biorender.com.](https://figures.cochat.ai/paper-figures/a0915283d9de4093ad444cf66d7c73d6/combination-therapies-for-the-optimisation-of-bispecific-t-cell-engagers-in-figure-1.jpg)
![Figure 2. Mechanism of BiTE-mediated tumour lysis. BiTEs form an immunological synapse between T-cells and TAA presenting cells by binding CD3 (most commonly, but other T-cell-associated targets such as CD28 or 4-1BB exist, as discussed below) and a TAA of choice. Binding of both arms of the BiTE activates the T-cell and leads to degranulation of cytotoxic perforins and granzyme B across the immunological synapse, leading to tumour cell lysis [2]. As the BiTE depicted directly targets CD3 on T-cells, activation occurs in a TCR-independent fashion that results in activation of a polyclonal population of T-cells. Crucially, BiTE-mediated tumour lysis would also perpetuate the cancer-immunity (depicted in Figure 1) because activated T-cells secrete immune activating cytokines, and tumour cell lysis leads to antigen release, uptake by APCs and subsequent immune activation (Figure 1; steps 4 and 1). Produced using biorender.com.](https://figures.cochat.ai/paper-figures/c1a8a8dbbe5a4995bd7b15254fc02f6a/combination-therapies-for-the-optimisation-of-bispecific-t-cell-engagers-in-figure-2.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“By linking two distinct single-chain variable fragments (scFvs), BiTEs target both a tumor-associated antigen and a TCR component necessary for T-cell activation, typically CD3 [85].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [85]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929 · cited 2×
“The cancer-immunity cycle (adapted from [1]).”
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104 · cited 1×
“The ABL1 944C→T (Thr315Ile) mutation is a known driver of TKI resistance in haematological malignancies [50].”
Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,533
Smith-Garvin, J. E., Koretzky, G. A., & Jordan, M. S. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132706 · Cited by 2,144
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Kantarjian, H., Stein, A., Gökbuget, N., Fielding, A. K., Schuh, A. C., Ribera, J.-M., Wei, A., Dombret, H., Foà, R., Bassan, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609783 · Cited by 2,143
Shimabukuro-Vornhagen, A., Gödel, P., Subklewe, M., Stemmler, H. J., Schlößer, H. A., Schlaak, M., Kochanek, M., Böll, B., & von Bergwelt-Baildon, M. S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0343-9 · Cited by 1,656
Immune checkpoint signaling and cancer immunotherapy
He, X., & Xu, C. (2020) · Cell Research · doi:10.1038/s41422-020-0343-4 · Cited by 1,371
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Galluzzi, L., Humeau, J., Buqué, A., Zitvogel, L., & Kroemer, G. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0413-z · Cited by 1,349
Long, G. V., Dummer, R., Hamid, O., Gajewski, T. F., Caglevic, C., Dalle, S., Arance, A., Carlino, M. S., Grob, J.-J., Kim, T. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30274-8 · Cited by 960 · cited 1×
“phase 3 trial for advanced melanoma despite promising preclinical data [80].”
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Nathan, P., Hassel, J. C., Rutkowski, P., Baurain, J.-F., Butler, M. O., Schlaak, M., Sullivan, R. J., Ochsenreither, S., Dummer, R., Kirkwood, J. M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103485 · Cited by 924
Research works printed but not linked: 1
- Litzow, 2022, Consolidation therapy with blinatumomab improves overall survival in newly diagnosed adult patients with B-lineage acute lymphoblastic leukemia in measurable residual disease negative remission: results from the ECOG-ACRIN E1910 randomized phase III National Cooperative Clinical Trials Network trial, LBA-1
Cited by
KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance
Ash, L. J., Busia-Bourdain, O., Okpattah, D., Kamel, A., Liberchuk, A., & Wolfe, A. L. (2024) · Current Oncology · doi:10.3390/curroncol31040150 · Cited by 68
Racacho, K. J., Shiau, Y., Villa, R., Mahri, S., Tang, M., Lin, T., & Li, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1621812 · Cited by 70
Innovative strategies for T cell engagers for cancer immunotherapy
Bergamaschi, C., Gaspar, M., Ciucci, T., Sitnikova, S. I., Cayatte, C., Pica, M., & Dovedi, S. J. (2025) · mAbs · doi:10.1080/19420862.2025.2531223 · Cited by 44
Immune Cell Engagers: Advancing Precision Immunotherapy for Cancer Treatment
In, H., Park, M., Lee, H., & Han, K. H. (2025) · Antibodies · doi:10.3390/antib14010016 · Cited by 35
Hadidi, S. A., Heslop, H. E., Brenner, M. K., & Suzuki, M. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.05.039 · Cited by 30
Advances in Cell and Immune Therapies for Melanoma
Timis, T., Buruiana, S., Dima, D. M., Nistor, M., Mureșan, X. M., Cenariu, D., Țigu, A. B., & Tomuleasa, C. (2025) · Biomedicines · doi:10.3390/biomedicines13010098 · Cited by 26
Kang, D. H., Lee, J., Im, S., & Chung, C. (2024) · Cancers · doi:10.3390/cancers16233996 · Cited by 23
Molldrem, J. J., & Zha, D. (2024) · Cancers · doi:10.3390/cancers16223776 · Cited by 19
Passariello, M., Manna, L., Lembo, R. R., Yoshioka, A., Inoue, T., Kajiwara, K., Hashimoto, S., Nakamura, K., & Lorenzo, C. D. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02329-8 · Cited by 16
Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma
Sam, J., Leclercq-Cohen, G., Gebhardt, S., Surowka, M., Herter, S., Lechner, K., Relf, J., Briner, S., Varol, A., Appelt, B., et al. (2025) · Blood · doi:10.1182/blood.2025028863 · Cited by 16
Ellerman, D. A. (2024) · BioDrugs · doi:10.1007/s40259-024-00691-0 · Cited by 13
Sultan, M. H., Zhang, Q., Wang, Y., Xia, Y., & Jia, X. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5545 · Cited by 11
Advancements in Immunotherapy for Breast Cancer: Mechanisms, Efficacy, and Future Directions
Rai, A., Deshpande, S. G., Vaidya, A., & Shinde, R. K. (2024) · Cureus · doi:10.7759/cureus.68351 · Cited by 20
Tavarozzi, R., Zacchi, G., Pietrasanta, D., Catania, G., Castellino, A., Monaco, F., Gandolfo, C., Rivela, P., Sofia, A., Schiena, N., et al. (2023) · Cancers · doi:10.3390/cancers15225397 · Cited by 12
Nahle, T., Shah, V., Farraj, S. A., & Atoui, A. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103704 · Cited by 12
Recent advances in cellular immunotherapy for lymphoid malignancies
Chung, H., & Cho, H. (2023) · Blood Research · doi:10.5045/br.2023.2023177 · Cited by 10
Ikhtiar, F., Jamal, A., & Bokhari, S. M. S. M. (2025) · Discover Oncology · doi:10.1007/s12672-025-03535-7 · Cited by 10
Muth, A., Holzem, A. M. E., Neumann, A.-S., Bücklein, V., Subklewe, M. S., & Philipp, N. (2026) · Med · doi:10.1016/j.medj.2026.101031 · Cited by 9
Wermke, M., Ochsenreither, S., Jaeger, D., Becker, H., Bleckmann, A., Bozorgmehr, F., Chatterjee, M., Groepper, S., Haenel, M., Hecker, J. S., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04455-x · Cited by 10
T cell exhaustion in pediatric B-ALL: current knowledge and future perspectives
Atre, T., & Reid, G. S. D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1531145 · Cited by 6
Ali, I., Faiza, M. R., Mehmood, A. K., Wang, Z., Zhang, F., & Zhang, X. (2026) · Journal of drug targeting · doi:10.1080/1061186x.2026.2687011 · Cited by 5
Structural insights into antibody-based immunotherapy for hepatocellular carcinoma
Shah, M., Hussain, M. S., & Woo, H. G. (2025) · Genomics & Informatics · doi:10.1186/s44342-024-00033-0 · Cited by 7
Improving CD3 bispecific antibody therapy in solid tumors using combination strategies
Lloyd, K. A., Middelburg, J., Ovcinnikovs, V., Pencheva, N., Kemper, K., & van Hall, T. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1548446 · Cited by 5
Advances in adoptive cell therapies in small cell lung cancer
Bragasin, E. I., Cheng, J. K., Ford, L., Poei, D., Ali, S., & Hsu, R. C. (2025) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2025.1002302 · Cited by 6
Breaking the Mold: Trailblazing Melanoma Therapy Beyond Checkpoint Through Innovative Approaches
Kidwai, N., Chen, M. F., Postow, M. A., Hassel, J. C., & Callahan, M. K. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_432462 · Cited by 5
Beyond Immune Checkpoint Inhibitors: Emerging Targets in Melanoma Therapy
Knight, A. D., & Luke, J. J. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01551-4 · Cited by 4
Li, Y., Wilkins, A. K., Davis, J. L., Knab, T., Toukam, M., Boni, J. P., & Kirouac, D. C. (2025) · npj Systems Biology and Applications · doi:10.1038/s41540-025-00544-8 · Cited by 3
Mellatyar, H., Sattari, S., Asl, A. N., & Akbarzadeh, A. (2024) · BioNanoScience · doi:10.1007/s12668-024-01389-x · Cited by 3
T-cell engagers in cancer immunotherapy: mechanisms, challenges, and future perspectives
Muthughavi, K., Khokhar, M., Jha, H. C., & Pandey, R. K. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1755512 · Cited by 2
Relapsed/refractory multiple myeloma: standard of care management of patients in the Gulf region
Alhuraiji, A., Farsi, K. A., Mheidly, K., Elsabah, H., Cherif, H., Hamad, A. A., Marashi, M., Al-Hateeti, H., Osman, H. Y., & Mohty, M. (2025) · Clinical Hematology International · doi:10.46989/001c.137860 · Cited by 3
Poppe, B., Praska, T., Camou, M., Edmond, A., & Niu, J. (2026) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2026.100955 · Cited by 1
Matching Patients With Cell Surface–Targeted Clinical Trials Using Large Language Models
Callahan, S. C., Chrostek, M. R., Rydzewski, N. R., Bootsma, M. L., Helzer, K. T., Bakhtiar, H., Morris, Z. S., Kosoff, D., Lang, J. M., Ma, V. T.-L., et al. (2026) · JCO Precision Oncology · doi:10.1200/po-25-00757 · Cited by 1
Paczesny, S., Barwe, S. P., Gopalakrishnapillai, A., & Cheung, N. V. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102772 · Cited by 2
Realizing the potential of agonistic antibody immunotherapy
Cragg, M. S., Yu, X., Paluch, C., & Davis, S. J. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01442-2 · Cited by 2
Bispecific T-Cell Engagers (BiTEs) in Immunotherapy
Sheykhhasan, M., La’ah, A. S., Ahmadieh-Yazdi, A., Tanzadehpanah, H., Mahaki, H., Manoochehri, H., Yang, P., Poondla, N., Kalhor, N., & Al-Musawi, S. (2024) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/979-8-3693-3976-3.ch006 · Cited by 1
MARCOCI, A., MANOLACHE, R. M., FLORESCU, R. B., Barbu, D., GRADINARU, F., Angelescu, S., Mambet, C., Jardan, C., BERBEC, N. M., & Coliţă, A. (2023) · Documenta Haematologica - Revista Romana de Hematologie · doi:10.59854/dhrrh.2023.1.4.207
Bispecific T-cell engagers in oral cancer immunotherapy
Priya, V. V. (2024) · Oral Oncology Reports · doi:10.1016/j.oor.2024.100255
Exploring the Blind Spots: The Role of Antigen Presentation Defects in Lung Cancer
Ozyapiciel, C. S., Cabri, R. E., & Korkut, M. G. (2025) · Current Molecular Biology Reports · doi:10.1007/s40610-025-00166-3
Yuan, N., Chen, C., Xu, F., Yang, H., Wang, Y., Liu, P., Li, Z., & Sun, P. (2025) · Annals of Hematology · doi:10.1007/s00277-026-07025-w
Smail, S. W., Flaih, A. H., Ismail, B. A., Ahmed, A. A., Bapir, A. A., Qadir, F. A., & Janson, C. (2026) · Immuno · doi:10.3390/immuno6020034
Bose, C. K. (2026) · Indian Journal of Medical and Paediatric Oncology · doi:10.1055/s-0046-1824552
An Overview on T-Cell Engagers: The Current Position in Both the Biological and Mathematical Context
Davies, J., Brown, L., Jones, M. W., Penny, M., & Powathil, G. (2026) · Computational and Structural Biotechnology Journal · doi:10.34133/csbj.0209
Key barriers in utilizing advanced T-cell engager strategies on solid tumors
Ku, B. M., Lim, S.-W., Uhm, J., Park, B.-B., & Ahn, M.-J. (2026) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2026.2730177
Cheikh, J. E., Wehbeh, B. E. D., Tarhini, A., Mansour, R., Sayde, G., Charbel, N., Kautaich, K., Hasan, I., & Refaat, M. M. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.09.019
Joseph, J. M., Tario, J. D., Yu, H., Parker, S., Lund, I., Slemmer, K., Schaefer, M. E., Celotto, K. L., Hassan, H., McCarthy, P., et al. (2026) · Cancers · doi:10.3390/cancers18213428
Bispecific T-cell engagers beyond hematology: Expanding uses in solid tumors
Rychalsky, K., Luon, D., & Tracchia, J. (2026) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552261500125
Metadata
- Authors
- Zhu, W. M., & Middleton, M. R.
- Affiliations
- University of Oxford (GB)
- Corresponding author
- Zhu, Winston M
- Venue
- Immunotherapy Advances
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-01-01
- Volume
- 3
- Issue
- 1
- Pages
- ltad013-ltad013
- ISSN
- 2732-4303 (ISSN-L)
- PMC
- PMC10439528
- OpenAlex
- W4385713649
- Cited by
- 46
- References
- 115
- Citations by year
- 2026: 15 · 2025: 17 · 2024: 11 · 2023: 3
- FWCI
- 1.49
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Immunotherapy Advances (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Roche
- AstraZeneca
- Novartis
- Millenium
- Immunocore
- Eisai
- Merck
- Rigontec
- BiolineRx
- Array Biopharma
- Pfizer
- Kineta
- Replimune
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- bispecific T-cell engagers, combination therapy, immune checkpoint, tumor microenvironment, T cell anergy, blinatumomab, immune checkpoint inhibitors, oncolytic viruses, costimulatory molecules, chemotherapy, solid tumors, cancer immunotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.